Updated NCCN Guidelines Recommend HEPZATO KIT for Hepatic-Dominant Uveal Melanoma
Source: OncLive, February 2025
The NCCN Guidelines for metastatic uveal melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease.
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for the treatment of metastatic uveal melanoma to include HEPZATO KIT ([melphalan] for Injection/Hepatic Delivery System [HDS]) as a Category 2A treatment option for patients with hepatic-dominant uveal melanoma.
The Guidelines had previously limited the use of HEPZATO KIT to the treatment of patients with liver-confined metastases.